Clinical observation on YiSuiShengXueGranule on treating 156 patients with β-thalassemia major and the molecular mechanism study

DOI Web Site Web Site 参考文献7件
  • Fang Suping
    Department of Molecular-Biology, Guang'AnMen Hospital, China Academy of Traditional Chinese Medicine
  • Wu Zhikui
    Department of Molecular-Biology, Guang'AnMen Hospital, China Academy of Traditional Chinese Medicine
  • Zhang Xinhua
    The 303 Hospital of People's Liberation Army of China
  • Liu Yongmei
    Department of Molecular-Biology, Guang'AnMen Hospital, China Academy of Traditional Chinese Medicine
  • Wang Wenjuan
    Department of Molecular-Biology, Guang'AnMen Hospital, China Academy of Traditional Chinese Medicine
  • Chai Limin
    Department of Molecular-Biology, Guang'AnMen Hospital, China Academy of Traditional Chinese Medicine
  • Cai Huiguo
    Institute of Hematology, Chinese Academy of Medical Sciences
  • Yi Jie
    Liaoning College of Traditional Chinese Medicine
  • Wang Lei
    Department of Molecular-Biology, Guang'AnMen Hospital, China Academy of Traditional Chinese Medicine
  • Chen Yuying
    Department of Molecular-Biology, Guang'AnMen Hospital, China Academy of Traditional Chinese Medicine
  • Lv Xinxia
    Department of Molecular-Biology, Guang'AnMen Hospital, China Academy of Traditional Chinese Medicine
  • Huang Youwen
    The 303 Hospital of People's Liberation Army of China
  • Wang Rongxin
    The 303 Hospital of People's Liberation Army of China
  • Chen Peizhen
    Institute of Hematology, Chinese Academy of Medical Sciences

書誌事項

タイトル別名
  • Clinical Observation on YiSuiShengXueGranule on Treating 156 Patients with .BETA.-Thalassemia Major and the Molecular Mechanism Study
  • Clinical observation on YiSuiShengXueGranule on treating 156 patients with v thalassemia major and the molecular mechanism study

この論文をさがす

説明

Objective: To investigate the clinical effects and security of YiSuiShengXueGranule (YSSXG) on treating 156 patients with β-thalassemia major. Methods: YSSXG was given orally to 156 patients with β-thalassemia in GuangXi Autonomous Region (the high incidence area of β-thalassemia in China) for 3 months as one therapeutic course, 3 times a day, 10 g each time (for children, the dose should be reduced properly according to their body weight and age), and no blood transfusion used during the course. Clinical symptoms and levels of hemoglobin (Hb), red blood cell (RBC), reticulocyte (Ret) and hemoglobin F (HbF) were observed before and after treatment, and side-effects were observed during the course. A 3—6 months follow up study was performed after withdrawal of YSSXG. And systemic gene analysis was conducted with PCR, SSCP-PCR, RT-PCR and DNA sequences analysis and mRNA differently expression technique, in order to study the molecular mechanism from the relationships between genetic mutation and clinical efficacy, gene expression and its regulation. Results: Levels of Hb, RBC, Ret and HbF obviously elevated, and clinical symptoms markedly meliorated in patients after treated with YSSXG from the 1st to 3rd month (all p<0.01). Dynamical observation showed that the improvement of symptoms kept accordance with the elevation of hemorrheological indexes. The treatment was effective in 145 patients and ineffective in 11, and the total effective rate was 92.9%, without any adverse reaction founded. Follow-up studies showed the therapeutic effect could sustain for 3 to 4 months after drug-withdrawal. The molecular mechanism study showed: YSSXG did not change the genetic mutation type, but could obviously increase γ/(β+γ) globin ratio, both γ-globin mRNA and GM-CSF mRNA expression were significantly enhanced so as to induce HbF synthesis increasing after treated with YSSXG. Conclusion: YSSXG had obviously effects in treating β-thalassemia by unlocking γ-gene, increasing the γ-globin expression and enhancing HbF synthesis so as to compensate for the gene defect. This study has provided a new path for the treatment of β-thalassemia with Traditional Chinese Medicine.

収録刊行物

参考文献 (7)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ